Stocks and Investing
Stocks and Investing
Mon, January 22, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, January 19, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ALLO) at Strong Buy with Decreased Target to $10 on, Jan 19th, 2024
Robert Burns of HC Wainwright & Co., Maintained "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Decreased Target from $12 to $10 on, Jan 19th, 2024.
Robert has made no other calls on ALLO in the last 4 months.
There are 4 other peers that have a rating on ALLO. Out of the 4 peers that are also analyzing ALLO, 2 agree with Robert's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Schmidt of "Guggenheim" Downgraded from Strong Buy to Hold on, Friday, January 5th, 2024
- Reni Benjamin of "JMP Securities" Downgraded from Buy to Hold on, Friday, January 5th, 2024
These are the ratings of the 2 analyists that currently disagree with Robert
- Samantha Semenkow of "Citigroup" Initiated at Strong Buy and Held Target at $7 on, Friday, December 8th, 2023
- Brian Cheng of "JP Morgan" Maintained at Buy with Decreased Target to $9 on, Monday, September 25th, 2023
Contributing Sources